Leaderboards/Peripheral Neuropathies and Disorders

Peripheral Neuropathies and Disorders

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Sadia Waheed
Memorial Healthcare System
2
Hannah G. Rosenblum
National Center for Immunization and Respiratory Diseases
3
Vitaly Polisky
Unknown
4
Kayla E. Hanson
Marshfield Clinic
5
Ingrid Jyssum
Diakonhjemmet Hospital
6
Sander J van Tilburg
Erasmus MC
7
Robin C.M. Thomma
Erasmus MC
8
Judith A. Restrepo
Harvard University
9
Lenka Súkeníková
ETH Zurich
10
Merel C. Broers
Health and Education Research Management and Epidemiologic Services (United States)

Papers

1
Autoreactive T cells target peripheral nerves in Guillain–Barré syndrome
Nature|2024
55 cit.
2
U.S. Women with Invasive Cervical Cancer: Characteristics and Potential Barriers to Prevention
Journal of Women s Health|2024
3 cit.
3
ABS1163 PERSONALISED ADALIMUMAB THERAPY: DEVELOPMENT OF AN ALGORITHM FOR THERAPEUTIC DRUG MONITORING
Annals of the Rheumatic Diseases|2025
0 cit.
4
Time intervals from vaccine administration to reimbursement for an updated Advisory Committee on Immunization Practices (ACIP) recommendation: Evidence from pneumococcal conjugate vaccinations among privately insured adults, 2021–2022
Vaccine|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Guest Editor Joseph Schwartz
Columbia University Irving Medical Center
2
Luís Querol
Hospital de Sant Pau
3
Dorothy P. Schafer
University of Massachusetts Chan Medical School
4
Filip Eftimov
Amsterdam University Medical Centers
5
Kajohnsak Noppakun
Chiang Mai University
6
Karissa Gable
Duke University
7
Susanna B. Park
The University of Sydney
8
Ryan S. Tonkin
UNSW Sydney
9
Chamini J. Perera
Ingham Institute
10
Sergio Iván Valdés‐Ferrer
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Papers

1
A comparative analysis of microglial inducible Cre lines
Cell Reports|2023
98 cit.
2
Epidemiological and clinical characteristics of patients with human monkeypox infection in Mexico: a nationwide observational study
The Lancet Regional Health - Americas|2022
64 cit.
3
Lipofuscin-like autofluorescence within microglia and its impact on studying microglial engulfment
Nature Communications|2023
50 cit.
4
Microglia-astrocyte crosstalk regulates synapse remodeling via Wnt signaling
Cell|2025
44 cit.
5
Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
Brain|2022
33 cit.
6
Elevated TNF-α Leads to Neural Circuit Instability in the Absence of Interferon Regulatory Factor 8
Journal of Neuroscience|2022
28 cit.
7
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes
Journal of the National Comprehensive Cancer Network|2023
25 cit.
8
An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy
Journal of the Peripheral Nervous System|2023
25 cit.
9
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases
Annals of the Rheumatic Diseases|2022
23 cit.
10
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations
Journal of Autoimmunity|2023
23 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Jerry S. Wolinsky
The University of Texas Health Science Center at Houston
2
Angela Vincent
University of Oxford
3
Brian G. Weinshenker
Mayo Clinic in Arizona
4
Nobuhiro Yuki
Dokkyo University
5
Richard AC Hughes
National Hospital for Neurology and Neurosurgery
6
Vanda A. Lennon
Mayo Clinic
7
Pieter A. van Doorn
Erasmus MC
8
Hugh J. Willison
University of Glasgow
9
Satoshi Kuwabara
Chiba University
10
Hans Link
Karolinska Institutet

Papers

1
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Annals of Neurology|2011
9.8k cit.
2
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
Annals of Neurology|2001
7k cit.
3
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Neurology|2015
4.5k cit.
4
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
The Lancet|2004
3.2k cit.
5
Revised diagnostic criteria for neuromyelitis optica
Neurology|2006
2.6k cit.
6
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
The Journal of Experimental Medicine|2005
2.3k cit.
7
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
New England Journal of Medicine|2016
1.9k cit.
8
The clinical course of neuromyelitis optica (Devic’s syndrome)
Neurology|1999
1.8k cit.
9
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY
Brain|1989
1.5k cit.
10
Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia
Brain|2010
1.3k cit.

Reagents for Peripheral Neuropathies and Disorders

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling Technology

Phospho-Estrogen Receptor (Ser104/106) Antibody

#2517
View Evidence →
Cell Signaling TechnologyEvidence 62

Rabbit (DA1E) Monoclonal Antibody IgG Isotype Control (Biotinylated)

#4096$176
View Evidence →
Cell Signaling TechnologyEvidence 66

VGLUT2 (D7D2H) Rabbit Monoclonal Antibody

#71555$161,351
View Evidence →

🌟 All-Time

Most validated

Innovative ResearchEvidence 72

Mouse Anti-Human CD1a Monoclonal Antibody, Alexa Fluor 488 Conjugated, Clone 143

Cited in 5 papers
#CD1A20
View Evidence →
Cell Signaling TechnologyEvidence 64

FGF Receptor 4 (D3B12) Rabbit Monoclonal Antibody

#8562$159,381
View Evidence →
Cell Signaling Technology

Phospho-p53 (Ser46) Antibody

#2521$148,362
View Evidence →